Release date: 23 February 2010
Promoter – Financial Intermediary
UCB S.A.
Location
Description
Financing of UCB’s pharmaceutical research and development for the period 2010-2014.
Objectives
The project will contribute to private sector investments in R&D, mostly located in Europe, thus meeting the orientations that underpin the Lisbon’s Council decision and the Bank’s Knowledge Economy (i2i), research and development.
Comments
The Risk Sharing Finance Facility (RSFF) is an innovative credit risk sharing scheme jointly set up by the European Commission and the European Investment Bank to improve access to debt financing for private companies or public institutions promoting activities with a higher financial risk profile in the fields of research, technological development, demonstration and innovation investments.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 250 million.
Total cost (Approximate amount)
EUR 539 million.
Environmental aspects
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA is therefore not required by EU Directive 97/11. Compliance of R&D activities with relevant EU legislation in particular in regards to animal testing will be also be verified during appraisal.
Procurement
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Status
Signed - 9/05/2012
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).